PEDIATRIX MEDICAL GROUP INC (MD) Stock Fundamental Analysis
NYSE:MD - New York Stock Exchange, Inc. - US58502B1061 - Common Stock - Currency: USD
Overall MD gets a fundamental rating of 3 out of 10. We evaluated MD against 108 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of MD have multiple concerns. MD has a bad growth rate and is valued cheaply.
1. Profitability
1.1 Basic Checks
In the past year MD was profitable.
In the past year MD had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: MD reported negative net income in multiple years.
MD had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of MD (-12.22%) is worse than 71.96% of its industry peers.
Looking at the Return On Equity, with a value of -34.65%, MD is doing worse than 68.22% of the companies in the same industry.
MD has a Return On Invested Capital of 7.43%. This is in the better half of the industry: MD outperforms 71.96% of its industry peers.
MD had an Average Return On Invested Capital over the past 3 years of 7.31%. This is in line with the industry average of 8.14%.
The last Return On Invested Capital (7.43%) for MD is above the 3 year average (7.31%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.22% | ||
| ROE | -34.65% | ||
| ROIC | 7.43% |
ROA(3y)1.64%
ROA(5y)-11%
ROE(3y)4.98%
ROE(5y)-38.31%
ROIC(3y)7.31%
ROIC(5y)6.29%
1.3 Margins
MD's Operating Margin of 8.20% is fine compared to the rest of the industry. MD outperforms 77.57% of its industry peers.
MD's Operating Margin has declined in the last couple of years.
The Profit Margin and Gross Margin are not available for MD so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.2% | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3Y-7.23%
OM growth 5Y-11.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), MD is destroying value.
There is no outstanding debt for MD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
MD has an Altman-Z score of 1.79. This is a bad value and indicates that MD is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.79, MD is in line with its industry, outperforming 44.86% of the companies in the same industry.
The Debt to FCF ratio of MD is 5.44, which is a neutral value as it means it would take MD, 5.44 years of fcf income to pay off all of its debts.
MD has a Debt to FCF ratio of 5.44. This is in the better half of the industry: MD outperforms 75.70% of its industry peers.
A Debt/Equity ratio of 0.83 indicates that MD is somewhat dependend on debt financing.
MD has a worse Debt to Equity ratio (0.83) than 62.62% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.83 | ||
| Debt/FCF | 5.44 | ||
| Altman-Z | 1.79 |
ROIC/WACC0.87
WACC8.51%
2.3 Liquidity
A Current Ratio of 1.42 indicates that MD should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.42, MD is in line with its industry, outperforming 45.79% of the companies in the same industry.
A Quick Ratio of 1.42 indicates that MD should not have too much problems paying its short term obligations.
The Quick ratio of MD (1.42) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.42 | ||
| Quick Ratio | 1.42 |
3. Growth
3.1 Past
MD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.25%, which is quite good.
The earnings per share for MD have been decreasing by -15.01% on average. This is quite bad
EPS 1Y (TTM)18.25%
EPS 3Y-2.95%
EPS 5Y-15.01%
EPS Q2Q%59.38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1.19%
3.2 Future
Based on estimates for the next years, MD will show a decrease in Earnings Per Share. The EPS will decrease by -1.32% on average per year.
Based on estimates for the next years, MD will show a small growth in Revenue. The Revenue will grow by 1.31% on average per year.
EPS Next Y5.67%
EPS Next 2Y5.47%
EPS Next 3Y-1.32%
EPS Next 5YN/A
Revenue Next Year-2.67%
Revenue Next 2Y0.1%
Revenue Next 3Y1.31%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 10.48, the valuation of MD can be described as very reasonable.
90.65% of the companies in the same industry are more expensive than MD, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 29.63. MD is valued rather cheaply when compared to this.
Based on the Price/Forward Earnings ratio of 9.91, the valuation of MD can be described as reasonable.
Compared to the rest of the industry, the Price/Forward Earnings ratio of MD indicates a rather cheap valuation: MD is cheaper than 87.85% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.68. MD is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.48 | ||
| Fwd PE | 9.91 |
4.2 Price Multiples
MD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MD is cheaper than 80.37% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, MD is valued cheaper than 87.85% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.64 | ||
| EV/EBITDA | 8.89 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PEG (NY)1.85
PEG (5Y)N/A
EPS Next 2Y5.47%
EPS Next 3Y-1.32%
5. Dividend
5.1 Amount
No dividends for MD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
15.61
-1.62 (-9.4%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners107.87%
Inst Owner Change-4.69%
Ins Owners1.46%
Ins Owner Change-0.64%
Market Cap1.34B
Analysts77.65
Price Target16.54 (5.96%)
Short Float %2.81%
Short Ratio3.93
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.56%
Min EPS beat(2)5.21%
Max EPS beat(2)15.9%
EPS beat(4)3
Avg EPS beat(4)5.24%
Min EPS beat(4)-4.41%
Max EPS beat(4)15.9%
EPS beat(8)3
Avg EPS beat(8)-2.64%
EPS beat(12)5
Avg EPS beat(12)-1.74%
EPS beat(16)8
Avg EPS beat(16)3.31%
Revenue beat(2)0
Avg Revenue beat(2)-1.83%
Min Revenue beat(2)-3.14%
Max Revenue beat(2)-0.52%
Revenue beat(4)0
Avg Revenue beat(4)-3.81%
Min Revenue beat(4)-7.9%
Max Revenue beat(4)-0.52%
Revenue beat(8)0
Avg Revenue beat(8)-2.99%
Revenue beat(12)1
Avg Revenue beat(12)-3.02%
Revenue beat(16)3
Avg Revenue beat(16)-2.75%
PT rev (1m)0%
PT rev (3m)39.98%
EPS NQ rev (1m)-0.46%
EPS NQ rev (3m)-0.46%
EPS NY rev (1m)-0.15%
EPS NY rev (3m)-0.15%
Revenue NQ rev (1m)-0.17%
Revenue NQ rev (3m)-0.17%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.48 | ||
| Fwd PE | 9.91 | ||
| P/S | 0.67 | ||
| P/FCF | 11.64 | ||
| P/OCF | 9.39 | ||
| P/B | 1.83 | ||
| P/tB | N/A | ||
| EV/EBITDA | 8.89 |
EPS(TTM)1.49
EY9.55%
EPS(NY)1.57
Fwd EY10.09%
FCF(TTM)1.34
FCFY8.59%
OCF(TTM)1.66
OCFY10.65%
SpS23.37
BVpS8.53
TBVpS-6.05
PEG (NY)1.85
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.22% | ||
| ROE | -34.65% | ||
| ROCE | 9.66% | ||
| ROIC | 7.43% | ||
| ROICexc | 8.53% | ||
| ROICexgc | 54.76% | ||
| OM | 8.2% | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | 5.74% |
ROA(3y)1.64%
ROA(5y)-11%
ROE(3y)4.98%
ROE(5y)-38.31%
ROIC(3y)7.31%
ROIC(5y)6.29%
ROICexc(3y)8.35%
ROICexc(5y)7.64%
ROICexgc(3y)55.37%
ROICexgc(5y)57.02%
ROCE(3y)9.51%
ROCE(5y)8.18%
ROICexcg growth 3Y-14.21%
ROICexcg growth 5Y21.04%
ROICexc growth 3Y-2.38%
ROICexc growth 5Y15.67%
OM growth 3Y-7.23%
OM growth 5Y-11.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.97
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.83 | ||
| Debt/FCF | 5.44 | ||
| Debt/EBITDA | 3.05 | ||
| Cap/Depr | 80.27% | ||
| Cap/Sales | 1.38% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 71.75% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.42 | ||
| Quick Ratio | 1.42 | ||
| Altman-Z | 1.79 |
F-Score4
WACC8.51%
ROIC/WACC0.87
Cap/Depr(3y)91.94%
Cap/Depr(5y)90.35%
Cap/Sales(3y)1.62%
Cap/Sales(5y)1.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.25%
EPS 3Y-2.95%
EPS 5Y-15.01%
EPS Q2Q%59.38%
EPS Next Y5.67%
EPS Next 2Y5.47%
EPS Next 3Y-1.32%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1.19%
Revenue Next Year-2.67%
Revenue Next 2Y0.1%
Revenue Next 3Y1.31%
Revenue Next 5YN/A
EBIT growth 1Y-5.62%
EBIT growth 3Y-2.8%
EBIT growth 5Y-8.67%
EBIT Next Year26.38%
EBIT Next 3Y12.91%
EBIT Next 5YN/A
FCF growth 1Y29.9%
FCF growth 3Y-16.05%
FCF growth 5Y-18.91%
OCF growth 1Y26.96%
OCF growth 3Y-12.44%
OCF growth 5Y-15.23%